FDA approves Pfizer's Hemophilia B Gene Therapy, Beqvez
Pfizer's groundbreaking $3.5 million gene therapy for hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine
Source: biopharma-reporter.com
Penn Comprehensive News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Penn Comprehensive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Penn Comprehensive Today - Breaking & Trending Today
U.S. FDA Approves Pfizer's BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds after up to three years of follow-up, providing sustained bleed protection and...
Source: marketscreener.com
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B.
Source: ajmc.com
FDA OKs Second Gene Therapy for Hemophilia B
One dose of fidanacogene elaparvovec proved noninferior to standard prophylactic factor IX
Source: medpagetoday.com
Pfizer Reinforces Commitment To Patients Living With Hemophilia
Pfizer Reinforces Commitment To Patients Living With Hemophilia
Source: peacefmonline.com